Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival

Sorafenib has been recommended as first- or second-line treatment for metastatic renal cell carcinoma (mRCC) by several guidelines. The objective of this study is to evaluate the efficacy of sorafenib monotherapy in Chinese patients with mRCC and determine the prognostic clinicopathologic factors as...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaoteng, Guo, Gang, Li, Xuesong, Zhang, Cuijian, Huang, Lihua, Fang, Dong, Song, Yi, Zhang, Xu, Zhou, Liqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602909/
https://www.ncbi.nlm.nih.gov/pubmed/26313773
http://dx.doi.org/10.1097/MD.0000000000001361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602909/
https://www.ncbi.nlm.nih.gov/pubmed/26313773
http://dx.doi.org/10.1097/MD.0000000000001361

Ejemplares similares